These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30517302)

  • 1. Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China.
    Kong J; Liu Z; Cai F; Xu X; LiuI J
    Clinics (Sao Paulo); 2018 Dec; 73():e455. PubMed ID: 30517302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy.
    Chen J; Luo X; Xie G; Chen K; Jiang H; Pan F; Li J; Ruan Z; Pang X; Liang H
    Medicine (Baltimore); 2016 May; 95(19):e3652. PubMed ID: 27175691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
    Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
    Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.
    Zhu ML; Wang M; Cao ZG; He J; Shi TY; Xia KQ; Qiu LX; Wei QY
    PLoS One; 2012; 7(7):e36293. PubMed ID: 22815677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
    Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
    J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between nucleotide excision repair gene polymorphism and colorectal cancer risk.
    Zhang Y; Wu S; Zhou X; Huang F; Chen R; Wang Y; Wu J
    J Clin Lab Anal; 2019 Oct; 33(8):e22956. PubMed ID: 31568607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.
    Negandhi AA; Hyde A; Dicks E; Pollett W; Younghusband BH; Parfrey P; Green RC; Savas S
    PLoS One; 2013; 8(4):e61469. PubMed ID: 23626689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
    Dai Q; Luo H; Li XP; Huang J; Zhou TJ; Yang ZH
    Mutagenesis; 2015 May; 30(3):441-9. PubMed ID: 25690281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.
    Kweekel DM; Antonini NF; Nortier JW; Punt CJ; Gelderblom H; Guchelaar HJ
    Br J Cancer; 2009 Jul; 101(2):357-62. PubMed ID: 19536092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.
    Sun K; Gong A; Liang P
    Tumour Biol; 2015 Mar; 36(3):1549-59. PubMed ID: 25355595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An association of selected ERCC2 and ERCC5 genes polymorphisms, the level of oxidative DNA damage and its repair efficiency with a risk of colorectal cancer in Polish population.
    Kabzinski J; Przybylowska K; Dziki L; Dziki A; Majsterek I
    Cancer Biomark; 2015; 15(4):413-23. PubMed ID: 25835182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association study between XPG Asp1104His polymorphism and colorectal cancer risk in a Chinese population.
    Du H; Zhang X; Du M; Guo N; Chen Z; Shu Y; Zhang Z; Wang M; Zhu L
    Sci Rep; 2014 Oct; 4():6700. PubMed ID: 25332048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
    Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
    Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms in five other nucleotide excision repair genes.
    Abbasi R; Ramroth H; Becher H; Dietz A; Schmezer P; Popanda O
    Int J Cancer; 2009 Sep; 125(6):1431-9. PubMed ID: 19444904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association between XPG Asp1104His and XPF Arg415Gln polymorphism and breast cancer risk: a meta-analysis of case-control studies.
    Ding DP; He XF; Zhang Y
    Breast Cancer Res Treat; 2011 Aug; 129(1):203-9. PubMed ID: 21424776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haplotype and diplotype analyses of variation in ERCC5 transcription cis-regulation in normal bronchial epithelial cells.
    Zhang X; Crawford EL; Blomquist TM; Khuder SA; Yeo J; Levin AM; Willey JC
    Physiol Genomics; 2016 Jul; 48(7):537-43. PubMed ID: 27235448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
    Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
    Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population.
    Li M; Chen R; Ji B; Fan C; Wang G; Yue C; Jin G
    Oncol Rep; 2021 Mar; 45(3):1295-1305. PubMed ID: 33469680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.